The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

New research published in The Journal of Clinical Investigation argues that Alzheimer’s may begin much earlier than ...

Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are ...

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost ...

Small actions today can help reduce your dementia risk.

Alzheimer’s disease affects millions of people around the world and is one of the leading causes of memory loss and cognitive ...

Smith Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory ...

A new Duke study is exploring whether cells inside the nose could reveal early signs of Alzheimer’s disease. Researchers say ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD), reports a new study at Columbia ...

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

Alzheimer’s disease is one of the most common causes of dementia in older adults. It is a progressive brain disorder that ...